In sum, results from studies in preclinical Alzheimer’s models support that targeting S2R with a small-molecule approach may be a beneficial therapeutic strategy by displacing synaptotoxic amyloid-β oligomers, and preventing synaptotoxicity, thereby enabling synapses to recover and slow cognitive decline [2,3]. This evidence concerns the gene TMEM97 and Mental deterioration.